Search hospitals
>
Kansas
>
Kansas City
University of Kansas Medical Center
Claim this profile
Kansas City, Kansas 66103
Global Leader in Parkinson's Disease
Global Leader in Breast Cancer
Conducts research for Heart Failure
Conducts research for Cystic Fibrosis
Conducts research for Stroke
1261 reported clinical trials
88 medical researchers
Summary
University of Kansas Medical Center is a medical facility located in Kansas City, Kansas. This center is recognized for care of Parkinson's Disease, Breast Cancer, Heart Failure, Cystic Fibrosis, Stroke and other specialties. University of Kansas Medical Center is involved with conducting 1,261 clinical trials across 1,274 conditions. There are 88 research doctors associated with this hospital, such as Dhanunjaya Lakkireddy, Jeffrey Statland, Andrea D. Jewell, and Rajesh Pahwa.
Area of expertise
Parkinson's Disease
University of Kansas Medical Center has run 57 trials for Parkinson's Disease. Some of their research focus areas include:
Breast Cancer
University of Kansas Medical Center has run 48 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Dhanunjaya Lakkireddy
Kansas City Cardiac Arrhythmia Research Foundation
3 years of reported clinical research
Jeffrey Statland
University of Kansas Medical Center
2 years of reported clinical research
Andrea D. Jewell
University of Kansas Cancer Center
6 years of reported clinical research
Rajesh Pahwa
University of Kansas Medical Center
6 years of reported clinical research
Clinical Trials running at University of Kansas Medical Center
Heart Failure
Stroke
Cystic Fibrosis
Smoking Cessation
Multiple Myeloma
Lung Cancer
Obesity
Pulmonary Hypertension
Parkinson's Disease
Prostate Cancer
Reprieve System
for Heart Failure
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.
Recruiting
2 awards
Phase 3
3 criteria
HeartMate 3 Device
for Heart Failure
Durable left ventricular assist devices (dLVAD) have been increasingly utilized since the mid to late 1990s, with an uptick of utility starting in 2010 following expanded indications for therapy to not only include a bridge to transplantation strategy, but also for those individuals who suffer from advanced heart failure (HF) and do not qualify for cardiac transplantation. Despite the decreasing size of the newest generation devices leading to a lessened occurrence of adverse events, bleeding and infection still remain a concern for clinicians, as well as a general lack of predictability towards adverse events in individuals with a dLVAD in place. There is a lack of description in the literature currently, regarding the interface between what the pump data provides and what is seen in clinical practice. There also is little known about the effects of what is provided in the pump data, in correlation to quality-of-life following dLVAD implantation. Therefore, the purpose of this study is to prospectively analyze normal and abnormal pump data through pump operations such as suction events, low flow alarms as well as other adventitious alarms, PI events and power cable disconnects greater than 20 seconds, from the HeartMate 3 ® dLVAD in order to clinically correlate this data to quality of life, frailty and other various medical conditions and adverse events as defined by the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). This will be achieved through two aims: 1) Evaluate the effectiveness of dLVAD pump operations data on clinical practice application (quality of life, frailty and various medical conditions, and adverse events such as GIB, RHF, infection, hypertension, arrhythmias and stroke); and 2) Evaluate correlations and relationships of longitudinal normal and abnormal dLVAD pump operations data, to demographic and clinical variables. This study is the first study to evaluate HeartMate 3 ® dLVAD pump operations data over time for effectiveness in the clinical practice.
Recruiting
1 award
N/A
2 criteria
Levosimendan
for Pulmonary Hypertension with Heart Failure
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Recruiting
1 award
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Kansas Medical Center?
University of Kansas Medical Center is a medical facility located in Kansas City, Kansas. This center is recognized for care of Parkinson's Disease, Breast Cancer, Heart Failure, Cystic Fibrosis, Stroke and other specialties. University of Kansas Medical Center is involved with conducting 1,261 clinical trials across 1,274 conditions. There are 88 research doctors associated with this hospital, such as Dhanunjaya Lakkireddy, Jeffrey Statland, Andrea D. Jewell, and Rajesh Pahwa.
Where is University of Kansas Medical Center located?
The University of Kansas Medical Center is located at 4000 Cambridge St, Kansas City, KS 66160-8501. Directions vary: from the North, take I-35 South from I-29 South; from the West, take I-70 East to 7th St. Trafficway South; from the East, take I-70 West to I-35 South to 7th St. Trafficway; from the South, take I-35 North to Rainbow Blvd., then south on Rainbow to 39th St. Public parking is available at Parking Garage P5.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Kansas Medical Center, patients without healthcare coverage can reach out to the Financial Counseling Center by calling 816-404-3000 or emailing GBC-FinancialCounselor@kumc.edu. They offer support in determining eligibility for commercial medical insurance, MO HealthNet (Medicaid), Crime Victims Compensation Fund, and the UH Financial Assistance Program, considering factors like residency, income, and family size. For insurance-related questions, please consult the contact details available on the University of Kansas Medical Center website.
What insurance does University of Kansas Medical Center accept?
The University of Kansas Medical Center accepts a wide range of insurance plans, including Blue Cross and Blue Shield, Aetna, Medicare Advantage, Medicaid, Aetna Better Health of Kansas, Home State Health Plan (MC+), and AARP/Secure Horizons Medicare Complete (UHC). Coverage extends to a variety of providers and facilities through the Blue Cross and Blue Shield network, encompassing the Kansas City metro area, greater Kansas, and nationwide. Additionally, employees of the University of Kansas Medical Center have access to medical, dental, and vision insurance, along with disability and long-term care, life insurance, and wellness programs.
What awards or recognition has University of Kansas Medical Center received?
The University of Kansas Cancer Center is recognized by the National Cancer Institute (NCI) as a "Comprehensive" cancer center, highlighting its dedication to research, education, and patient care. The University of Kansas Health System is a Magnet®-designated hospital, acknowledged for delivering superior patient care and achieving optimal outcomes. It has also been continuously accredited by The Joint Commission since 2008.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.